Pas­cal So­ri­ot, lamenter of low pay, faces in­vestor re­volt for be­ing over­com­pen­sat­ed

As­traZeneca CEO Pas­cal So­ri­ot once be­moaned his $13 mil­lion an­nu­al salary, call­ing him­self the “low­est-paid CEO in the whole in­dus­try.”

Now, af­ter his new, $18.5 mil­lion pack­age came to light last month, As­traZeneca’s in­vestors are com­plain­ing: They think So­ri­ot is over­paid.

As­traZeneca is fac­ing a share­hold­er re­volt over So­ri­ot’s pay pack­age, Sky News re­ports, with in­vestors warn­ing that they plan to vote against the com­pa­ny’s re­mu­ner­a­tion re­port and pol­i­cy at its an­nu­al meet­ing on April 29. The cen­tral is­sue is the an­nu­al amount put in­to So­ri­ot’s pen­sion. In­vestors have de­mand­ed the British drug­mak­er re­duce it from 30% to the av­er­age pen­sion award for a British work­er. In­stead, they cut it to 20% — still well above the av­er­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER